SELLAS Life Sciences Group, Inc. SLS Proceeds From Warrant Exercises
Proceeds From Warrant Exercises at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.
The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about SELLAS Life Sciences Group, Inc.'s proceeds from warrant exercises.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is SELLAS Life Sciences Group, Inc.'s proceeds from warrant exercises?
- SELLAS Life Sciences Group, Inc. (SLS) reported proceeds from warrant exercises of $44.08M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s proceeds from warrant exercises changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s proceeds from warrant exercises increased by 8664.2% year-over-year, from $503K to $44.08M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s proceeds from warrant exercises?
- Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s proceeds from warrant exercises has grown at a 42.4% compound annual growth rate (CAGR), from $3.07M to $12.62M.
- What does proceeds from warrant exercises mean?
- This metric represents the cash received by the company when holders of warrants exercise their right to purchase common stock. It indicates the conversion of derivative instruments into permanent equity capital. A higher value suggests that warrant holders are incentivized to invest further in the company, providing non-dilutive-like cash inflows.